Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Rabobank has contributed to Gilde Healthcare’s third private equity fund, which will focus on established and profitable businesses in the Benelux and Dach countries.

Oregon Venture Fund and Rogue Venture Partners have both backed University of Oregon's DNA testing services provider NemaMetrix to bring the spinout’s total to $8.5m.

Health for Life Capital II has achieved its first close thanks to commitments from strategic partners Danone, Novartis, Lesaffre, Wright Medical, Unicéréales and Bel.

GV participated as a new investor, as Harvard's genetic medicine developer Beam Therapeutics completed a round that followed $87m in series A funding last year.

ETH’s Paul Scherrer Institute has launched Araris Biotech to deliver production technology for site-specific ADCs that enable them to be used without being engineered from each patient.

Satt Sud-Est spinouts Click4Tag, C4Hydro and C4Biocontrol will merge to boost the commercialisation of microbe monitoring technologies built on research from six institutions.

University of Tokyo’s Utec has extended its foray into Indian VC investments by starting an accelerator in partnership with local venture fund Blume Ventures.

GV participated as a new investor, as genetic medicine developer Beam Therapeutics completed a round that followed $87m in series A funding last year.

The rechargeable hearing aid producer has now raised more than $144m altogether, having collected about $52m in a series D round featuring Nan Fung Life Sciences.